Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC). Patients received capecitabine 2500 mg m(2) day 1, orally divided in two doses of 1250 mg m(−2) in the morning and evening for 14 da...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rao, S, Cunningham, D, Price, T, Hill, M E, Ross, P J, Tebbutt, N, Norman, A R, Oates, J, Shellito, P
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2004
Assuntos:
Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409883/
https://ncbi.nlm.nih.gov/pubmed/15266319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados